These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21126631)

  • 1. Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide. Introduction and overview.
    San-Miguel JF
    Blood Rev; 2010 Nov; 24 Suppl 1():S1-3. PubMed ID: 21126631
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in multiple myeloma: current role and future directions.
    Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
    Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenalidomide in multiple myeloma.
    Kim Y; Schmidt-Wolf IG
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide: a new therapy for multiple myeloma.
    Palumbo A; Miguel JS; Sonneveld P; Moreau P; Drach J; Morgan G; Einsele H
    Cancer Treat Rev; 2008 May; 34(3):283-91. PubMed ID: 18230411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
    Klein U; Jauch A; Hielscher T; Hillengass J; Raab MS; Seckinger A; Hose D; Ho AD; Goldschmidt H; Neben K
    Cancer; 2011 May; 117(10):2136-44. PubMed ID: 21523726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
    Fukushima T; Nakamura T; Iwao H; Umehara H
    Am J Hematol; 2011 Oct; 86(10):893. PubMed ID: 21812018
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
    Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
    Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
    [No Abstract]   [Full Text] [Related]  

  • 18. Concluding remarks and future directions.
    San-Miguel JF
    Blood Rev; 2010 Nov; 24 Suppl 1():S33-4. PubMed ID: 21126635
    [No Abstract]   [Full Text] [Related]  

  • 19. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
    Palumbo A; Dimopoulos M; San Miguel J; Harousseau JL; Attal M; Hussein M; Knop S; Ludwig H; von Lilienfeld-Toal M; Sonneveld P
    Blood Rev; 2009 Mar; 23(2):87-93. PubMed ID: 18774632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunomodulator drugs for the treatment of multiple myeloma].
    Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
    Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.